ClinicalTrials.gg
Status unknownNCT03763123Updated Dec 4, 2018

A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.

A Phase 1 interventional study of Sevacizumab and Paclitaxel in Ovarian Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Status unknown at 6 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-04.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2018, registered Nov 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 393 studies in Ovarian Neoplasms with a site in China — 199 open to participants now, 231 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
204th of 320
48 · median 83
Started
2018
with 16 others
Phase 1
70 of 393
37 open now
Registered
66th of 393
by date

Among the 393 studies in Ovarian Neoplasms with a site in China, this one is the 204th largest by planned enrollment of the 320 interventional ones that give a count, is one of 17 that started in 2018, is one of 70 in phase 1, and was the 66th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

199 of the 393 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

194 more — sign in →

All 199 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 393 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with Chemotherapy in Chinese patients with Platinum-Resistant Recurrent Ovarian Cancer. This study includes two stages. Stage 1 is the dose-escalation stage. Once the maximum tolerated dose (MTD of Sevacizumab has been established, additional patients will be enrolled in the cohort-expansion stage (Stage 2).

Read the detailed description

This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with Chemotherapy in Chinese patients with Platinum-Resistant Recurrent Ovarian Cancer. This study includes two stages. Stage 1 is the dose-escalation stage. Once the maximum tolerated dose (MTD of Sevacizumab has been established, additional patients will be enrolled in the cohort-expansion stage (Stage 2).

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age≥18 years
  2. documented platinum resistant
  3. EOC, FTC, or PPC of the following types: adenocarcinoma not otherwise specified (NOS), clear cell adenocarcinoma, endometriod adenocarcinoma, malignant Brenner's tumor, mixed epithelial carcinoma, mucinous adenocarcinoma, serous adenocarcinoma, transitional cell carcinoma and undifferentiated carcinoma.
  4. At least one measurable leision. (according to 1.1 )
  5. performance status (ECOG PS) 0-1.
  6. Adequate hematologic function: ≥ 1.5 × 10\^9 /L, HB ≥ 90 g /L (blood transfusion allowed), ≥ 100 ×10\^9 /L; Adequate hepatic function: ≤ 2.5 × , AST ≤ 2.5 × ULN, ≤ 1.5 × ULN (patients with liver ALT ≤ 5 × ULN, AST ≤ 5 × ULN); Adequate renal function: creatinine ≤ 1 × ULN; Coagulation function: ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN
  7. Progression within 6 months from completion of a minimum of 4 platinum therapy cycles.
  8. ≥12 weeks.
  9. At least 4 weeks from the last chemotherapy. If patients received anti-tumor biological products, at least four t1/2 of is needed
  10. Toxicity from previous treatment has to restore to ≤ grade 1 (NCI CTC4.0)
  11. Patients signed written inform consent.
  12. Willingness and capability to communicate with investigators and to comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with > 2 anti-cancer regimens.
  2. Patients whose disease was to their previous platinum treatment. (Refractory disease was defined as those patients who progressed during the preceding platinum treatment.)
  3. Ovarian tumors with low malignant potential (i.e. borderline tumors).
  4. Patients with a prior invasive (except non-melanoma skin cancer) or whose prior malignancy treatment the current protocol therapy.
  5. Any prior radiotherapy to the pelvis or abdomen.
  6. Patients with serious non-healing wound, ulcer, or bone fracture.
  7. patients with a history of bowel obstruction (including subocclusive disease) related to underlying disease, a history of abdominal fistula, GI perforation, or intra-abdominal abscess or evidence of rectosigmoid involvement by pelvic examination, bowel involvement on computed tomography, or clinical symptoms of bowel obstruction.
  8. Serious infection requiring intravenous antibiotic therapy
  9. history or evidence of thrombotic or hemorrhagic disorder within 6 months before first study treatment
  10. untreated CNS disease unrelated to cancer or symptomatic
  11. Patients with cardiovascular disease. This included:Uncontrolled hypertension, defined as systolic > 150 mmHg or diastolic > 90 mmHg;Myocardial infarction or unstable angina > 6 months prior to registration; (NYHA) Grade II or greater congestive heart failure;Serious cardiac arrhythmia requiring medication. This did not include asymptomatic, atrial fibrillation with controlled ventricular rate.
  12. below the institutional lower limit of normal
  13. pre-existing neuropathy ≥ CTC Grade 2 for those in the paclitaxel group
  14. Known allergies to any in the study drug
  15. Pregnant and lactating women
  16. Patients with proteinuria (urine protein >1+ at screening, or urine protein 1+, not recover to normal value within 24h)
  17. Previously received anti-VEGF protein drugs, such as Bevacizumab, Sevacizumab
  18. Patients with or with anticipation of invasive procedures as defined below:Major surgical procedure or significant traumatic injury within 28 days prior to the first date of sevacizumab therapy;Major surgical procedure anticipated during the course of the study. This included, but was not limited to abdominal surgery (laparotomy or laparoscopy) prior to disease progression;Core , within 7 days prior to randomization.
  19. Participation in other clinical trials within 4 weeks before enrollment
  20. The investigators consider the patients are not suitable for this trial.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Sevacizumab +Chemotherapy Combined chemotherapy drug including

    Investigators selected single-agent chemotherapy on an individual patient basis from the following options, with appropriate premedication according to local standards: paclitaxel 80mg/m2 intravenously (IV)on days 1, 8, 15, and 22 every 4 weeks; or topotecan 4 mg/m2 IV on days 1, 8, and 15 every 4 weeks.

    Drug: Sevacizumab · Drug: Paclitaxel · Drug: Topotecan

Interventions

  • Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg,1mg/kg,1.5mg/kg and 2mg/kg

  • paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;

  • topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    Time frame: 3 years

  2. The ratio of adverse of event

    Time frame: 3 years

Secondary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Maximum Plasma Concentration \[Cmax\]

    Time frame: 3 years

  2. Area Under the Curve [AUC],

    Area Under the Curve \[AUC\]

    Time frame: 3 years

  3. Tmax

    Tmax for Cmax of sevacizumab

    Time frame: 3 years

  4. Objective Response Rate (ORR)

    Time frame: 3 years

  5. Disease Control Rate (DCR)

    Time frame: 3 years

  6. Overall Survival (OS)

    Time frame: 3 years

  7. Progression Free Survival (PFS)

    Time frame: 3 years

07

Study locations

5 of 6 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing, China
    Recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing, China
    Recruiting
  • The first affiliated hospital,sun yat-sen university
    Guangzhou, Guangdong, China
    Recruiting
    • Yao Shuzhong · Contactyszlfy@163.com · 020-87755766
    • Yao Shuzhong · Contactyszlfy@163.com · 02087755766
    • Yao Shuzhong · Principal investigator
  • the Affiliated Cancer Hospital of Harbin Medical University
    Harbin, Hei Longjiang, China
    Suspended
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Recruiting
  • Wuhan Union Hospital
    Wuhan, Hunan, China
    Recruiting
    • Li Guiling · Contactlgl6714@163.com · 027-83691785
    • Li Guiling · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Dec 2019, 20 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 20 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2018
First posted
Dec 4, 2018
StartActual
Apr 24, 2018
Primary completionEst.
Dec 31, 2019
CompletionEst.
Dec 31, 2020
Last update
Dec 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03763123
Responsible party
Sponsor
First posted
Dec 4, 2018
Start date
Apr 24, 2018
Primary completion
Dec 31, 2019 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Dec 4, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvemcitug

Start the discussion